Efficacy and optimized dosage of botulinum toxin type A injection for treatment of Acne vulgaris, enlarged pore, and oiliness: A randomized placebo-controlled trial

Srinakharinwirot University0 sites75 target enrollmentOctober 25, 2023

Overview

No summary available.

Registry

who.int

Start Date

October 25, 2023

End Date

April 29, 2024

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

•1\. Healthy patients age 18 to 45 years old, 2\. Patients with moderate acne vulgaris according to Clinical practice guideline of acne of Dermatological society of Thailand, 3\. Consent to study

•1\. Received a forehead injection of botulinum toxin within 6 months before the study, 2\. Received a forehead injection of hyaluronic acid (HA), biostimulator, or mesotherapy within 6 months before the study, 3\. Received the systemic treatments before the study (3\.1 Anti\-inflammatory drugs or drugs that have an effect on the treatment of acnes such as oral corticosteroids, oral antibiotics, oral contraceptive pills or oral zinc supplement within 1 month before the study, 3\.2 Drugs in retinoid group such as oral isotretinoin within 3 months before the study), 4\. Received the topical drugs for acne such as topical antibiotics, topical retinoids, or topical corticosteroids within 1 month before the study, 5\. History of botulinum toxin A allergy or allergy to any ingredients in botulinum toxin type A, 6\. History of botulinum toxin A resistance, 7\. History of neuromuscular disorders such as myasthenia gravis, Lambert\-Eaton syndrome, 8\. Current or active facial bacterial, fungal, or viral infection, 9\. Pregnancy or lactation, 10\. Cannot follow up throughout the study period